RCD advises Iteria Biopharma on €5M financing round
RCD has advised Iteria Biopharma on a €5 million financing round aimed at advancing the development of its prostate cancer treatment pipeline.
Iteria Biopharma, a biotech company focused on the development of novel therapies for advanced metastatic cancers, will use the proceeds to complete the regulatory preclinical development of its metastatic prostate cancer drug candidate and launch its first clinical trial.
The funding will also support the advancement of additional oncology projects targeting pancreatic, colorectal and lung cancer.
The team
The transaction was advised by an RCD team led by David Pintos.
